Breaking News Instant updates and real-time market news.

TSN

Tyson Foods

$63.33

0.36 (0.57%)

, SYY

Sysco

$55.31

0.71 (1.30%)

20:25
05/07/17
05/07
20:25
05/07/17
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Tyson Foods (TSN), consensus $1.02... Sysco (SYY), consensus 51c... Tower Semiconductor (TSEM), consensus 43c... Snyder's-Lance (LNCE), consensus 14c... Mallinckrodt (MNK), consensus $1.63... Horizon Pharma (HZNP), consensus 23c.

TSN

Tyson Foods

$63.33

0.36 (0.57%)

SYY

Sysco

$55.31

0.71 (1.30%)

TSEM

TowerJazz

$21.35

0.02 (0.09%)

LNCE

Snyder's-Lance

$34.22

0.32 (0.94%)

MNK

Mallinckrodt

$46.63

0.83 (1.81%)

HZNP

Horizon Pharma

$15.58

0.31 (2.03%)

  • 07

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 15

    May

  • 17

    May

  • 22

    May

  • 30

    May

  • 06

    Jun

  • 09

    Jun

  • 19

    Jun

  • 20

    Jun

  • 20

    Jun

  • 10

    Jul

  • 11

    Jul

TSN Tyson Foods
$63.33

0.36 (0.57%)

04/25/17
PIVT
04/25/17
NO CHANGE
Target $40
PIVT
Sell
Tyson Foods targets are aggressive, says Pivotal Research
Pivotal Research analyst Timothy Ramey said Tyson Foods' (TSN) synergy targets for the AdvancePierre Foods (APFH) are aggressive. Tyson expects $200M in cost synergies over three years, implying the adjusted EBITDA margins soaring to 31.8% from 19.1% in three years, which the analyst finds unlikely. Ramey said the overall margins for Prepared Food are flattish even with these "tremendous" synergies and maintained its Sell rating and a $40 price target.
03/16/17
03/16/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Biogen (BIIB) was downgraded to Equal Weight from Overweight at Morgan Stanley and Market Perform from Outperform at Leerink. 2. United Continental (UAL) downgraded to In Line from Outperform at Evercore ISI. 3. Tyson Foods (TSN) downgraded to Hold from Buy at Argus with analyst John Staszak citing the SEC probe of Tyson and other poultry producers, potential decelerating earnings in coming quarters, and a recent bird flu outbreak in two states. 4. Williams-Sonoma (WSM) downgraded to Market Perform from Outperform at William Blair with analyst Daniel Hofkin citing the company's fourth quarter results. 5. Inovio (INO) downgraded to Neutral from Overweight at Piper Jaffray with analyst Charles Duncan saying a "lack of focus and advancement for any one program" poses execution risk to the broader platform, and to shareholders. The analyst lowered his price target for the shares to $9 from $13 following the company's Q4 results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/16/17
ARGS
03/16/17
DOWNGRADE
ARGS
Hold
Tyson Foods downgraded on probe, earnings outlook, bird flu at Argus
As noted earlier, Argus downgraded Tyson Foods to Hold from Buy. As reasons for the downgrade, analyst John Staszak cited the SEC probe of Tyson and other poultry producers, potential decelerating earnings in coming quarters, and a recent bird flu outbreak in two states.
03/16/17
ARGS
03/16/17
DOWNGRADE
ARGS
Hold
Tyson Foods downgraded to Hold from Buy at Argus
SYY Sysco
$55.31

0.71 (1.30%)

02/07/17
02/07/17
UPGRADE
Target $59

Outperform
Sysco upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Edward Kelly upgraded Sysco to Outperform from Neutral as he sees the selloff as an opportunity to own a blue-chip company in an attractive industry, with solid underlying operating momentum, and insulation from many of the structural issues plaguing the consumer sector today. He also raised his price target on the shares to $59 from $55.
02/07/17
02/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Buy from Neutral at Citi with analyst Robyn Karnauskas saying the Alzheimer's Phase 2 data already reported and no Phase 3 results until 2019/20, upside in the stock rests on the stability of Biogen's multiple sclerosis business and success of the Spinraza launch in spinal muscular atrophy. 2. Caterpillar (CAT) upgraded to Overweight from Equal Weight at Barclays with analyst Robert Wertheimer saying investors likely will never get a chance to buy the company's revenue with as much upside as in 2017. 3. Sysco (SYY) upgraded to Overweight from Neutral at JPMorgan with analyst John Ivankoe saying the shares should be bought in the low $50s. He raised his price target for the shares to $57 from $55. 4. Nokia (NOK) upgraded to Overweight from Equal Weight at Morgan Stanley. 5. UBS (UBS) upgraded to Neutral from Underperform at BofA/Merrill with analyst Andrew Stimpson saying negative catalysts have played out. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/17
BMOC
05/04/17
UPGRADE
BMOC
Outperform
Sysco upgraded to Outperform from Market Perform at BMO Capital
05/04/17
BMOC
05/04/17
UPGRADE
BMOC
Outperform
Sysco upgraded on attractive attributes at BMO Capital
As noted earlier, BMO Capital upgraded Sysco to Outperform from Market Perform. Analyst Kelly Bania says that investors may rotate into Sysco, given what she sees as the company's "similar financial profile to consumer staple stocks" and its lower risk compared with many of the names in that category. The analyst says that food service volumes appear to be steady, while the company is more protected from Amazon (AMZN) than many consumer staple names. Target to $60 from $56.
TSEM TowerJazz
$21.35

0.02 (0.09%)

11/15/16
NEED
11/15/16
NO CHANGE
Target $25
NEED
Strong Buy
Tower Semiconductor price target raised to $25 from $20 at Needham
Needham analyst Rajvindra Gill raised his price target for Tower Semiconductor to $25 citing utilization improvements and free cash flow growth following the company's better than expected Q3 results. The analyst keeps a Strong Buy rating on Tower shares.
12/19/16
NEED
12/19/16
NO CHANGE
Target $25
NEED
Strong Buy
Tower Semiconductor named top pick for 2017 at Needham
Needham analyst Rajvindra Gill says his top stock pick for 2017 is Tower Semiconductor, noting that it has gained market share in the CMOS image sensor space as well as in the RF front-end module space and continues to ramp utilization rates. Moreover, the analyst believes the stock current levels represent an opportunity for investors to capitalize on a continual net profit, margins, and free cash flow growth story. He reiterates a Strong Buy and $25 price target on the shares.
02/14/17
CHLM
02/14/17
NO CHANGE
Target $30
CHLM
Buy
Tower Semiconductor price target raised to $30 from $26 at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for Tower Semiconductor to $30 from $26 after the company delivered another record quarter with solid revenue growth and growing margins. The analyst reiterates a Buy rating on the shares.
03/14/17
NEED
03/14/17
DOWNGRADE
NEED
Hold
Mobileye downgraded to Hold from Buy at Needham
Needham analyst Rajvindra Gill downgraded Mobileye (MBLY) to Hold from Buy after Intel (INTC) announced its intention to acquire all of the former's outstanding ordinary shares for $63.54 per share. The analyst believes the deal clearly validates the ADAS and fully autonomous vehicle market, and views it as a positive read-through into the entire ADAS and automotive supply chain, namely ON Semiconductor (ON), Micron (MU), Cypress Semiconductor (CY), NXP Semiconductors (NXPI), NVIDIA (NVDA), Tower Semiconductor (TSEM), and Infineon (IFNNY).
LNCE Snyder's-Lance
$34.22

0.32 (0.94%)

03/22/17
UBSW
03/22/17
INITIATION
Target $44
UBSW
Neutral
Snyder's-Lance initiated with a Neutral at UBS
UBS analyst Steven Strycula started Snyder's-Lance with a Neutral rating and $44 price target. The analyst prefers to wait for a more favorable entry point into the shares.
04/17/17
RHCO
04/17/17
DOWNGRADE
RHCO
Hold
Snyder's-Lance downgraded to Hold from Buy at SunTrust
04/17/17
04/17/17
DOWNGRADE
Target $30

Hold
Snyder's-Lance downgraded after guidance cut, CEO departure at SunTrust
As previously reported, SunTrust analyst William B. Chappell, Jr. downgraded Snyder's-Lance to Hold from Buy after the company's Q1 results missed estimates, its guidance was lowered, and its CEO departed, saying he has limited confidence that trends will improve in the near-term and sees limited catalysts over the next few quarters. The analyst lowered his price target on Snyder's-Lance shares to $30 from $45.
04/18/17
UBSW
04/18/17
NO CHANGE
Target $37
UBSW
Neutral
Better visibility needed to be more constructive on Snyder's-Lance, says UBS
UBS analyst Steven Strycula questioned whether Snyder's-Lance shares were oversold with yesterday's 15% move lower following its profit warning. Strycula noted it caught investors off-guard, as did the company's swift CEO change. The analyst said despite its selloff, the shares did not get cheaper on a near-term basis and for him to get more constructive he would need more visibility, which will hopefully be addressed on the its May 8 earnings call. Strycula maintained his Neutral rating and lowered his price target to $37 from $44 on Snyder's-Lance shares.
MNK Mallinckrodt
$46.63

0.83 (1.81%)

02/22/17
UBSW
02/22/17
NO CHANGE
Target $77
UBSW
Buy
UBS says FDA suspension for generic Concerta review a positive for Mallinckrodt
UBS analyst Marc Goodman noted the FDA agreed to suspend the deadline for submitting documentation in support of a hearing on the FDA's proposal to withdraw Mallinckrodt's ANDA for its generic Concerta. The entire process could take until the end of 2017, if not longer, said Goodman, who was only modeling one quarter of sales for generic Concerta, leaving potential for some upside, he tells investors. Goodman believes the delay is a modest positive for the stock and he reiterated his Buy rating and $77 price target on Mallinckrodt shares.
03/13/17
JEFF
03/13/17
NO CHANGE
Target $70
JEFF
Buy
Mallinckrodt price target lowered to $70 from $95 at Jefferies
Jefferies analyst Anthony Petrone lowered his price target for Mallinckrodt to $70 after updating his estimates. 2017 is a transitional year for the company, but "clearer skies" are ahead, Petrone tells investors in a research note. Acthar growth is supported by the data build out and volume gains, while Mallinckrodt's pipeline is being underappreciated, Petrone tells investors in a research note. The analyst notes that healthcare policy change will be gradual. He keep a Buy rating on Mallinckrodt.
03/31/17
PIPR
03/31/17
NO CHANGE
Target $83
PIPR
Overweight
Piper stays bullish on Mallinckrodt after management meetings
After traveling with management, Piper Jaffray analyst David Amsellem says he's staying bullish on Mallinckrodt. Management appears to be exploring all capital deployment options with the goal of driving multiple expansion, Amsellem tells investors in a research note. The company remains focused on further diversifying away from Acthar, he adds. Amsellem believes going private "should at least be explored." The analyst has an Overweight rating on Mallinckrodt with an $83 price target.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Novartis results highlight tough pricing environment, says Wells Fargo
This morning's Q1 results from Novartis' (NVS) Sandoz division highlight the difficult U.S. generic price environment, Wells Fargo analyst David Maris tells investors in a research note. Sandoz experienced pricing erosion of 8% in the quarter, which represents the largest negative impact from pricing in recent quarters, Maris writes. He expects the negative U.S. pricing environment to impact including Mallinckrodt (MNK), Teva (TEVA), Mylan (MYL) and Perrigo (PRGO). Maris remains cautious on the pricing environment for generics.
HZNP Horizon Pharma
$15.58

0.31 (2.03%)

01/30/17
PIPR
01/30/17
NO CHANGE
Target $32
PIPR
Overweight
Piper doctor survey shows 'ample room' for Procysbi growth
Piper Jaffray analyst David Amsellem says his firm's survey of 25 physicians who treat patients with nephropathic cystinosis points to "ample room" for growth of Horizon Pharma's Procysbi. The feedback points to a strong likelihood of significant longer-term growth for the product, Amsellem tells investors in a research note. He believes Horizon is well positioned to post long-term annual earnings growth of at least in the mid-teens. The analyst reiterates an Overweight rating on the shares with a $32 price target.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
12/16/16
COWN
12/16/16
NO CHANGE
COWN
Cowen says to add to Horizon Pharma positions
Cowen analyst Ken Cacciatore said Horizon (HZNP) has secured formulary status with Express Scripts (ESRX) for its specialty products. The analyst believes the "cleansing" of the Horizon story is now complete and is now positioned for growth. Cacciatore believes Horizon Pharma's base business supports a much higher valuation and reiterates his Outperform rating and $42 price target.
12/16/16
MZHO
12/16/16
UPGRADE
MZHO
Buy
Horizon Pharma upgraded to Buy from Neutral at Mizuho

TODAY'S FREE FLY STORIES

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

ITEK

Inotek Pharmaceuticals

17:04
01/19/18
01/19
17:04
01/19/18
17:04
Hot Stocks
Boxer Capital reports 5.3% passive stake in Rocket Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$32.80

0.35 (1.08%)

17:03
01/19/18
01/19
17:03
01/19/18
17:03
Syndicate
Breaking Syndicate news story on Oil States »

Oil States files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

, QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

16:43
01/19/18
01/19
16:43
01/19/18
16:43
Hot Stocks
Broadcom receives second request from FTC for proposed Qualcomm deal »

Broadcom (AVGO) announced…

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRNC

tronc

$19.53

0.3 (1.56%)

16:37
01/19/18
01/19
16:37
01/19/18
16:37
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, WSJ says »

Ross Levinsohn, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.